Featured
“Ready for it? Pfizer taps Kansas City Chiefs star Travis Kelce for latest Covid booster campaign”
The football player (and his mom) also star in the latest Pfizer ad campaign promoting Covid-19 vaccinations
Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, and Hepalys Pharma, Inc., a company incorporated in Japan and incubated by Catalys Pacific, have entered into an exclusive licensing agreement (the “Agreement”) to develop and commercialize Inventiva’s proprietary drug candidate lanifibranor for the treatment of non-alcoholic steatohepatitis (NASH) in Japan and South Korea.
AcuraStem Enters into a License Agreement with Takeda to Advance PIKFYVE Therapeutics
AcuraStem, a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases, announced today that it has entered into a license agreement with Takeda to develop and commercialize AcuraStem's PIKFYVE targeted therapeutics including AS-202, an innovative antisense oligonucleotide (ASO) for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver Diseases
Alfasigma S.p.A (“Alfasigma”), one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT, “Intercept”), a leading biopharmaceutical company in rare and serious liver diseases, today announced that they have entered into a definitive merger agreement under which Alfasigma has agreed to acquire Intercept for $19.00 per share in cash. The anticipated transaction will materially expand Alfasigma’s gastrointestinal and hepatology portfolio and its presence in the U.S. market.
UK drug giant AstraZeneca to set up research base in Hong Kong, city’s finance chief Paul Chan reveals on Europe work trip
Leading global pharmaceutical firm AstraZeneca will set up a research and development centre in Hong Kong, the city’s finance minister has revealed while on a work trip in Europe.
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
The ADSs are expected to begin trading on the Nasdaq Global Market on September 29, 2023 under the ticker symbol “ANL”.
Wuhan YZY Biopharma – HK$176 Million IPO
Wuhan YZY Biopharma offered a total of 11,001,200 H shares, priced at $16 per H share.
United States and China launch economic and financial working groups with aim of easing tensions
The U.S. Treasury Department and China’s Ministry of Finance launched a pair of economic working groups on Friday in an effort to ease tensions and deepen ties between the nations.
Pharming shortlisted for prestigious Scrip awards 2023
Pharming shortlisted in two categories, including “Biotech Company of the Year” and “Best New Drug”
